Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Acta Neurochirurgica
Published in: Acta Neurochirurgica 5/2016

01-05-2016 | Editorial (by Invitation)

A quest towards personalised medicine for grade II meningiomas—will need to zoom in

Authors: Thomas Santarius, Michael D. Jenkinson, Ramez W. Kirollos

Published in: Acta Neurochirurgica | Issue 5/2016

Login to get access

Excerpt

Champeaux and Dunn [2] have analysed the outcomes of grade II meningiomas (atypical, clear cell and choroid) resected in the Southern General Hospital in Glasgow between January 2000 and August 2015. The authors first identified cases that were classified as grade 2 according to the classification used at the time of surgery. The histological reports (not the histological slides themselves) were carefully reviewed and cases from before 2007 were reclassified according to the WHO 2007 classification of the tumours of the central nervous system [10] (further referred to as WHO 2007 classification). In the end, 206 cases were included in the study and only two patients were lost to follow-up. The median follow-up was 4.1 years, with the interquartile range of 1.6–7.3 years. …
Literature
1.
Backer-Grøndahl T, Moen BH, Torp SH (2012) The histopathological spectrum of human meningiomas. Int J Clin Exp Pathol 5(3):231–242PubMedPubMedCentral
2.
Champeaux C, Dunn L (2016) World Health Organization grade II meningiomas. A 10-year retrospective study on overall survival and associated prognostic factors. Acta Neurochir (Wein). doi:10.​1007/​s00701-016-2771-y
3.
Curtis C, Shah SP, Chin S-F et al (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486(7403):346–352PubMedPubMedCentral
4.
Gajjar A, Pfister SM, Taylor MD, Gilbertson RJ (2014) Molecular insights into pediatric brain tumors have the potential to transform therapy. Clin Cancer Res 20(22):5630–5640CrossRefPubMedPubMedCentral
5.
Gousias K, Schramm J, Simon M (2016) The Simpson grading revisited: aggressive surgery and its place in modern meningioma management. J Neurosurg 1–10
6.
Jenkinson MD, Javadpour M, Haylock BJ et al (2015) The ROAM/EORTC-1308 trial: radiation versus observation following surgical resection of atypical meningioma: study protocol for a randomised controlled trial. Trials 16:519CrossRefPubMedPubMedCentral
7.
Kleihues P, Cavenee WK (2000) World Health Organization classification of tumours—pathology and genetics. Tumours of the nervous system. IARC Press, Lyon
8.
Kleihues P, Burger PC, Scheithauer BW (1993) Histological typing of tumours of the central nevous system. Springer, BerlinCrossRef
9.
Kshettry VR, Ostrom QT, Kruchko C, Al-Mefty O, Barnett GH, Barnholtz-Sloan JS (2015) Descriptive epidemiology of World Health Organization grades II and III intracranial meningiomas in the United States. Neuro-Oncology 17(8):1166–1173CrossRefPubMed
10.
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) (2007) WHO classification of tumours of the central nervous system. IARC, Lyon
11.
Marcus HJ, Price SJ, Wilby M, Santarius T, Kirollos RW (2008) Radiotherapy as an adjuvant in the management of intracranial meningiomas: are we practising evidence-based medicine? Br J Neurosurg 22(4):520–528CrossRefPubMed
12.
Rogers L, Barani I, Chamberlain M, Kaley TJ, McDermott M, Raizer J, Schiff D, Weber DC, Wen PY, Vogelbaum MA (2014) Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg 1–20
13.
14.
Sughrue ME, Kane AJ, Shangari G, Rutkowski MJ, McDermott MW, Berger MS, Parsa AT (2010) The relevance of Simpson Grade I and II resection in modern neurosurgical treatment of World Health Organization Grade I meningiomas. J Neurosurg 113(5):1029–1035CrossRefPubMed
Metadata
Title
A quest towards personalised medicine for grade II meningiomas—will need to zoom in
Authors
Thomas Santarius
Michael D. Jenkinson
Ramez W. Kirollos
Publication date
01-05-2016
Publisher
Springer Vienna
Published in
Acta Neurochirurgica / Issue 5/2016
Print ISSN: 0001-6268
Electronic ISSN: 0942-0940
DOI
https://doi.org/10.1007/s00701-016-2774-8

Other articles of this Issue 5/2016

Acta Neurochirurgica 5/2016 Go to the issue

Editorial (by Invitation)

Deep brain stimulation and glioma

Letter to the editor - Functional

The effect of dopaminergic therapy on intraoperative microelectrode recordings for subthalamic deep brain stimulation under GA: Letter to the editor

CLINICAL ARTICLE - SPINE

Lumbar spinal canal dimensions measured intraoperatively after decompression are not properly rendered on early postoperative MRI

Clinical Article - Brain Injury

Management and outcome of low velocity penetrating head injury caused by impacted foreign bodies

Clinical Article - Functional

Combined surgical intervention with vagus nerve stimulation following corpus callosotomy in patients with Lennox-Gastaut syndrome

Case Report - Brain Tumors

Cochlear implants in the etiopathogenesis of glioblastoma–an interesting observation or independent finding?